Abstract. Advanced hepatocellular carcinoma (HCC) is insensitive to traditional chemotherapeutic approaches, which causes difficulty in the development of novel agents for the treatment of HCC. Berberine is the main component of Coptidis Rhizoma, a plant alkaloid with a long history of use in Chinese medicine, and has become a potential candidate for the treatment of HCC due to its high antitumor activity and low toxicity. In this study, we investigated the mechanism via which berberine exerts its inhibitory effects on HCC. The data demonstrated that berberine selectively decreased cell viability in a time-and dose-dependent manner in the HepG2, SMMC-7721 and Bel-7402 HCC cell lines compared with normal hepatocytes (HL-7702 cells), as determined by a sulforhodamine B assay. Flow cytometric analysis revealed that berberine increased the number of late apoptotic cells. Pretreatment with berberine in HepG2 cells resulted in a significant increase in phosphorylated AMP-activated protein kinase (AMPK), as well as a marked elevation in phosphorylated Akt levels. In addition, the activation of AMPK was accompanied by apoptotic effects that occurred in a caspase-dependent manner through the mitochondrial pathway, and was coupled with the release of cytochrome c from the mitochondria and the activation of caspase-9 and -3. Furthermore, the ratio of Bax/Bcl-2 was increased in a dose-dependent manner. Our study supports the theory that berberine selectively inhibits the growth of human hepatocellular cancer cells by inducing AMPK-mediated caspase-dependent mitochondrial pathway cell apoptosis, and rarely causes cytotoxicity in normal cells. Therefore, berberine is a promising novel agent for the treatment of HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common and aggressive malignant tumor types worldwide. The incidence of HCC has markedly increased to >600,000 cases annually, and HCC has become the second most common cause of mortality in China (1, 2) . Numerous risk factors, including chronic infection with hepatitis B and C viruses, alcohol-related cirrhosis and non-alcoholic fatty liver diseases, are closely correlated with the occurrence and development of HCC (3) (4) (5) . Furthermore, a large percentage of patients with advanced HCC require systemic or selective chemotherapy to achieve a longer life expectancy. Unfortunately, the overall survival rate remains poor with the use of traditional chemotherapy, as HCC is insensitive to conventional cytotoxic agents (6, 7) . Therefore, there is a significant requirement for the development of innovative treatment approaches to improve patient outcome.
AMP-activated protein kinase (AMPK) is a metabolic sensing protein kinase that acts as an important energy sensor, mainly in ATP-deprived conditions (8) . Therefore, AMPK is known to play a major protective role under conditions of metabolic stress. In the activated state, AMPK downregulates several anabolic enzymes and thus turns off ATP-consuming metabolic pathways (9, 10) . Several studies have observed the strong pro-apoptotic potential of AMPK in activated conditions, including AMPK activator (AICAR)-treated cells or constitutively active AMPK mutants (11) . Collectively, these studies highlight the importance of AMPK as a direct therapeutic target in all stages of cancer.
Berberine, an alkaloid purified from the Berberis species (Fig. 1) , has been extensively studied and is known to exhibit multiple pharmacological activities, including antiprotozoal, antihypertensive, antibacterial, anti-inflammatory, anticholinergic and anti-arrhythmic effects (12) (13) (14) . Previous studies have demonstrated that berberine has anticancer activities against several types of cancer, to include liver cancer (15, 16) . Berberine has been demonstrated to induce apoptosis in numerous cultured cancer cell lines (17, 18) ; however, the molecular mechanisms underlying berberine-induced apoptosis and the pathways involved have not been fully elucidated to date. In the present study, we aimed to inves-tigate the inhibitory effect of berberine on HCC cell lines and determine whether berberine-induced apoptosis was correlated with the AMPK-mediated caspase-dependent mitochondrial pathway.
Materials and methods
Reagents. Berberine (purity, >99%), sulforhodamine B (SRB) and protease inhibitors were purchased from Sigma-Aldrich (St. Louis, MO, USA). The high-glucose medium, Dulbecco's Modified Eagle's Medium (DMEM), was obtained from Gibco-BRL (Carlsbad, CA, USA). The Bradford Protein Assay kit, RIPA lysis buffer and the Annexin V-FITC Apoptosis Detection kit were purchased from Beyotime Institute of Biotechnology (Jiangsu, China). Activated signaling pathways were identified using primary antibodies, including anti-AMPK, anti-phosphospecific AMPK, anti-Akt, anti-phosphospecific Akt, anti-Bax, anti-Bcl-2, anti-cytochrome c, anti-caspase-3 and anti-caspase-9, purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The internal control antibody (anti-β-actin) was also obtained from Santa Cruz Biotechnology, Inc.
Cell culture. The human hepatocelluar carcinoma cell lines (HepG2, SMMC-7721 and Bel-7402) and the normal liver cell line (HL-7702) were purchased from Hsiang-Ya Medical College (Hunan, China). Cells were cultured at 37˚C and 5% CO 2 in DMEM supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 mg/ml). The study was approved by the ethics committee of Sichuan University.
Cell treatment and cell viability assay. The in vitro cytotoxicity of berberine against HepG2, SMMC-7721, Bel-7402 and HL-7702 cells was assessed using the traditional SRB assay. The SRB assay is routinely used for cytotoxicity determination, based on the measurement of live cell protein content (19) . In brief, cells were seeded into 96-well plates at a density of 7,000 cells/well. Following 24 h of culture in DMEM supplemented with 10% FBS, the medium was replaced with DMEM without FBS for 24 h. Subsequently, the cells were treated with berberine at final concentrations of 3.125, 6.25, 12.5, 25, 50 and 100 µM for 24 or 48 h prior to the SRB assay. All experiments were conducted in parallel with controls; at 24 or 48 h, 100 µl of 10% trichloroacetic acid was also added to each well when staining for 30 min, and then the excess dye was removed by washing repeatedly with 1% acetic acid. The protein-bound dye was dissolved in 10 mM Tris Base solution (Santa Cruz Biotechnology, Inc.) for optical density (OD) determination at 570 nm using a microculture reader (Bio-Rad, Richmond, CA, USA). The percentage of viable cells was calculated as follows: (A of experimental group/A of control group) x100, where A represents the absorbance. Western blot assay. The cells were washed twice with cold phosphate-buffered saline (PBS) and then suspended in RIPA buffer for 30 min on ice. The supernatant was collected as the total protein extract. The protein concentration was estimated by the Bradford Protein Assay kit (Beyotime Institute of Biotechnology), according to the manufacturer's instructions. Equal amounts of protein (40 µg) were analyzed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with a 5 or 12% separation gel, and molecular weight markers were run simultaneously. The proteins were transferred to nitrocellulose membranes and then blocked for 2 h at room temperature in a solution of 5% milk or bovine serum albumin (BSA). Incubation with the appropriate primary antibodies was performed overnight at 4˚C. Membranes were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit or anti-mouse secondary antibody (1:2,000 dilution) for 2 h at room temperature with gentle agitation. After washing, bands were visualized by an Enhanced Chemiluminescence (ECL) Western Blotting Detection system (Amersham Pharmacia Biotech, NJ, USA).
Apoptosis assays by flow cytometry (FCM)
Statistical analysis. All data were expressed as the mean ± SE. The statistical significance of differences in the data was determined by Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

Berberine inhibits cell viability in HCC cell lines in a time-and dose-dependent manner.
To evaluate the antitumor characteristics of berberine, cell viability was measured by a standard SRB assay following brief exposure to berberine (24 or 48 h). As demonstrated in Fig. 2 , berberine significantly reduced cell viability in human hepatoma cell lines in a time-and dose-dependent manner. Subsequently, we predicted the side effects of berberine by exposing the normal hepatic cell line, HL-7702, to the agent. The IC 50 values in the HL-7702 cell line (838.4 µM) at 48 h were markedly higher than those of the HCC cell lines (34.5 µM, 25.2 µM and 53.6 µM in the HepG2, SMMC-7721 and Bel-7402 cell lines, respectively). The differences in the IC 50 values indicated that berberine was able to selectively decrease the cell viability of HCC cells compared with normal hepatocytes. ) compared with the control group, in a dose-dependent manner (Fig. 3A) . At a concentration of 50 µM, berberine led to ≤40% apoptosis in HepG2 cells (Fig. 3B) . These results suggested that berberine-induced apoptosis in the liver cancer cells contributed to its antiproliferative and cytotoxic effects.
Berberine induces apoptosis via the mitochondrial-dependent pathway. In chemically induced apoptosis, mitochondria play a central role in the commitment of cells to apoptosis through cytochrome c-dependent pathways. To elucidate the molecular mechanism of berberine-induced apoptosis in HCC cells, we examined the expression of proteins associated with apoptosis. HepG2 cells were treated with 12.5 and 50 µM berberine for 24 h. The results demonstrated that creatine kinase induces the release of cytochrome c from mitochondria to the cytosol in dose-dependent manner (data not shown). Caspase-9 and -3, well-known downstream molecules of cytochrome c, were also cleaved in a concentration-dependent manner (Fig. 4A) . We further evaluated the effect of berberine on the mitochondrial apoptosis signaling pathway. We found that the expression of Bcl-2 protein, an anti-apoptotic molecule, decreased in a dose-dependent manner, whereas the expression of the pro-apoptotic protein, Bax, was significantly increased (Fig. 4B) . Furthermore, the ratio of Bax/Bcl-2 was increased in a dose-dependent manner (Fig. 4C) . These results indicated that treatment with berberine leads to a shift indicated that AMPK activation is correlated with the induction of apoptosis.
Discussion
HCC has a higher prevalence and mortality rate compared with other types of cancer. Therefore, prolonging survival times and improving quality of life have become main objectives in the treatment and management of patients with advanced HCC. The antitumor property of berberine has recently attracted increasing research attention (22) . A crucial advantage for the use of natural products as an alternative to the chemotherapeutic approach is their low cytotoxicity. In the present study, we examined the effect of berberine on cell viability and apoptosis in normal and cancer cells. We observed that berberine suppressed cell growth in a dose-and time-dependent manner in human HepG2, SMMC-7721 and Bel-7404 HCC cell lines. This indicates that the inhibitory effect of berberine in liver cancer is non-species-specific, and is associated with the previously reported types of HCC cells (23) . The normal control liver cell line, HL-7702, exhibited decreased cell viability. Berberine is one of the key components of Coptis chinesis, which is frequently utilized in proprietary Chinese herbal drugs and exerts a wide range of pharmacological effects. Berberine exhibits high antitumor activity in various types of tumors through different mechanisms (16, 17, 24) . A number of factors, including cytokines, chemokines, receptors and downstream elements within signaling cascade pathways, are correlated with apoptosis induced by berberine. Berberine has been demonstrated to induce apoptosis in human HCC cells via Fas-mediated (15) inhibition of the mTOR-signaling pathway (16) , downregulation of MMP-9 expression (25) and the nuclear factor-κB (NF-κB) and activator protein 1 (AP-1) pathways (26) . In the current study, we demonstrated that berberine had cytotoxic effects in HepG2 cells, including annexin V binding, cytochrome c release and activation of caspases, indicated by the increased cleavage of caspase-9 and -3, via caspase-dependent mitochondrial pathway cell apoptosis.
The association between cancer and AMPK emerges as an intriguing area of investigation. Numerous studies have indicated that the AMPK pathway is implicated in cancer. While traditionally regarded as a sensor of cellular energy status and a regulator of metabolism, AMPK has been linked to tumor suppressors, including LKB1, p53, TSC1 and TSC2, providing novel support for the theory that AMPK may function as a suppressor of cell proliferation (27) . There has been much speculation on the role of AMPK in cancer, as this pathway may be either anti-apoptotic or pro-apoptotic depending on the conditions (28) . The results of the present study demonstrated that treatment with berberine promoted AMPK phosphorylation and inhibited Akt phosphorylation in HepG2 cells, which led to caspase-dependent mitochondrial pathway cell apoptosis.
In conclusion, to the best of our knowledge, our results demonstrate for the first time that berberine exerts a selective antitumor effect on human liver cancer cells when compared with non-tumorigenic HL-7702 normal liver cells. Additionally, our data provide support to the theory that AMPK may be involved in the antitumor effect of berberine via caspase-dependent mitochondrial pathway cell apoptosis. These findings provide a molecular basis for the antiproliferative activity of berberine, which may be used as a potent and alternative chemotherapeutic agent for the treatment of HCC.
